Loading...
Biogen's experimental Alzheimer's drug, Leqembi, has shown promising results in a study, slowing cognitive decline in patients. The drug, which is administered through an under-the-skin injection, has been found to be as effective as the approved infused formulation. Biogen also reported 'favorable trends' in patients taking its experimental Alzheimer's therapy. An early study found that an experimental version of Eisai Co.'s Alzheimer's drug, which can be given in patients' homes, exceeded the power of Leqembi. The study could pave the way for increased uptake of the drug.
"Legislation expands access to breakthrough Alzheimer’s treatments" (@TheHillOpinion) https://t.co/ISJBfukJ5u https://t.co/qQlGhRZjk3
"Legislation expands access to breakthrough Alzheimer’s treatments" (@TheHillOpinion) https://t.co/BsrDlbzt4n https://t.co/q7OWdYXjai
"Legislation expands access to breakthrough Alzheimer’s treatments" (@TheHillOpinion) https://t.co/ty2tDx1Gkr https://t.co/XaRa8JJQr3
Since gene therapy was first proposed to treat genetic diseases in the 1970s, it has had thrilling highs and deeply troubling lows. https://t.co/kCr20lz32M
Why diagnosing Alzheimer’s early is so important https://t.co/ijNsVrzHWV
Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi https://t.co/nxKrdu2ygk https://t.co/6zz5TluslE
Physicians are dramatically underdiagnosing early cognitive decline, a precursor to Alzheimer’s https://t.co/eVc774F6Xu
More convenient form of breakthrough Alzheimer's drug Leqembi shows promising results in study https://t.co/DZPJA5827O
An experimental version of Eisai Co.’s Alzheimer’s drug that might be given in patients’ homes exceeded the power of Leqembi, its approved infused formulation, in an early study that could pave the way to bolstering uptake. https://t.co/2MULL2AjR7
New studies find benefits in very early drug treatment of Alzheimer’s https://t.co/Xy0yK8hP0Y
Under-the-skin injection of Eisai’s Leqembi is as effective as IV infusion, new Alzheimer’s data show https://t.co/LZnnH5kIqk $BIIB $LLY #CTAD23
Biogen’s tau-lowering drug slows cognitive decline in early study of #Alzheimers disease. https://t.co/L6ZBJn02OS
Are #oligos the future of #Alzheimer's? After $ALNY's robust APP knockdown, $BIIB reports favorable trends in clinical outcomes from its #tau-ASO licensed from $IONS in early study: https://t.co/hUEmI2WkO5
Biogen said it saw “favorable trends” in patients taking its experimental Alzheimer’s disease therapy https://t.co/W69OqeiUBN
$BIIB Biogen’s tau-lowering drug slows cognitive decline in early study of Alzheimer’s disease https://t.co/l4uogfTtxj #CTAD23
Araclon Biotech has provided early evidence that its Alzheimer’s vaccine is effective, linking the candidate to a 38% slowdown in disease progression compared to placebo in an exploratory analysis of phase 2 data. https://t.co/QR8OMqZbKw
We may finally know how cognitive reserve protects against Alzheimer's https://t.co/V7AJkWvExf
The FDA has approved eight gene therapies for rare genetic diseases. Each puts a healthy copy of a gene into cells to compensate for a missing or mutated one. https://t.co/kCr20lz32M
Diet can be key to preventing or reversing dementia, studies show https://t.co/3ye0FKffBv https://t.co/PMoR4RPRO5
We may finally know how cognitive reserve protects against Alzheimer's https://t.co/3WXrYzHTba